Bloomberg: Takeda may face 10,000 Actos claims

When the FDA found that the Takeda Pharmaceutical drug Actos might actually increase the risk of bladder cancer, the lawsuits were inevitable. Now, lawyers tell Bloomberg that the Japanese drugmaker may end up fighting as many as 10,000 claims in U.S. courts. To prepare for the onslaught, some U.S. judges are considering where to consolidate the legal battles.

As Bloomberg reports, plaintiffs' attorney Paul Pennock was due to appear in Savannah, GA, court today to argue for consolidation in Louisiana or Ohio. Pennock represents 1,200 Actos patients and expects to add many more. "We are getting calls every day about Actos," he told the news service.

Takeda spokesman Mitsuo Oguri told the news service that the company has already revised U.S. and Japanese patient-information materials to include risk data on bladder cancer. It's in the process of updating patient leaflets in Europe, the spokesman said, adding, "Takeda remains confident on the efficacy of pioglitazone for treating type 2 diabetes, while it continues to monitor the safety profile of the medicine."

- see the Bloomberg story

Special Report: Takeda Pharmaceutical - 10 Largest U.S. Patent Losses

Related Articles:
FDA highlights cancer risk with Takeda's Actos
French officials force Takeda to pull Actos off market
EMA wants Actos warning, weighs in on Chantix

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.